Dr. Reddy's Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Dr. Reddy's Laboratories Ltd. from all sources in a single place.

Load latest

Dr. Reddy's Laboratories Ltd.

04 Sep 2024

1224.20

0.43%

Dr Reddy's, Lupin recall products in US due to manufacturing issues: USFDA

Business Standard

Dr Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories Inc, a subsidiary of Hyderabad-based drug firm, is recalling Ibuprofen tablets in multiple strengths, the US health regulator said in its latest enforcement report. Ibuprofen tablets are indicated for pain relief and fever. New Jersey-based Dr Reddy's Laboratories Inc. is recalling 1,03,298 bottles (800 mg); 31,802 bottles (600 mg); and 14,940 bottles (400 mg) of Ibuprofen tablets in the US market, USFDA said. The company is recalling the affected lot due to "Failed impurities/degradation specifications," it added. "Results for unknown impurity were 0.13 per cent and 0.11 per cent, respectively, exceeding the 0.10 per cent specification limit," USFDA noted. The company initiated the Class II nationwide recall on August 6 this year. USFDA stated that Lupin is recalling 4,554 bottles of Cefixime for Oral Suspen

Dr. Reddy's Laboratories Ltd. is trading below its 150 day SMA of 1231.2

Dr. Reddy's Laboratories Ltd.

02 Sep 2024

1224.20

0.43%

Dr Reddy's declines 3% after China's regulator bans import of ADHD drug

Business Standard

Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.

Dr. Reddy's Laborato.. has an average target of 1357.00 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

31 Aug 2024

1224.20

0.43%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

30 Aug 2024

1224.20

0.43%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Schedule of Analyst / Institutional Investor Meeting

pdf

Dr. Reddy's Laboratories Ltd.

29 Aug 2024

1224.20

0.43%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Allotment of shares on exercise of Employee Stock Options

pdf

Dr. Reddy's Laboratories Ltd.

23 Aug 2024

1224.20

0.43%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

23 Aug 2024

1224.20

0.43%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure Under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Dr. Reddy's Laboratories Ltd.

23 Aug 2024

1224.20

0.43%

Dr. Reddy's - U.S., Europe Drive Growth: Nirmal Bang

NDTV Profit

Strong growth is expected in the generic segment in the near term in the U.S. business on the back of new launches and stable base business performance, says the brokerage.